| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2983 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2039 | 2017 |
| Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807, 2020 | 788 | 2020 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276-282, 2018 | 682 | 2018 |
| Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ... Jama 318 (9), 825-835, 2017 | 460 | 2017 |
| Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ... Clinical Cancer Research 24 (17), 4154-4161, 2018 | 431 | 2018 |
| Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations ZI Hu, J Shia, ZK Stadler, AM Varghese, M Capanu, E Salo-Mullen, ... Clinical Cancer Research 24 (6), 1326-1336, 2018 | 358 | 2018 |
| Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation EM O’Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ... Journal of Clinical Oncology 38 (13), 1378-1388, 2020 | 325 | 2020 |
| An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions MA Lowery, DP Kelsen, ZK Stadler, KH Yu, YY Janjigian, E Ludwig, ... The oncologist 16 (10), 1397-1402, 2011 | 281 | 2011 |
| Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677, 2021 | 270 | 2021 |
| Identification of germline genetic mutations in patients with pancreatic cancer EE Salo‐Mullen, EM O'Reilly, DP Kelsen, AM Ashraf, MA Lowery, KH Yu, ... Cancer 121 (24), 4382-4388, 2015 | 223 | 2015 |
| Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms MA Lowery, W Wong, EJ Jordan, JW Lee, Y Kemel, J Vijai, D Mandelker, ... JNCI: Journal of the National Cancer Institute 110 (10), 1067-1074, 2018 | 210 | 2018 |
| Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study MA Lowery, HA Burris, F Janku, RT Shroff, JM Cleary, NS Azad, L Goyal, ... The lancet Gastroenterology & hepatology 4 (9), 711-720, 2019 | 202 | 2019 |
| Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ... Clinical Cancer Research 23 (20), 6094-6100, 2017 | 184 | 2017 |
| FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma E Sadot, A Doussot, EM O’Reilly, MA Lowery, KA Goodman, RKG Do, ... Annals of surgical oncology 22, 3512-3521, 2015 | 166 | 2015 |
| Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition JJ Harding, MA Lowery, AH Shih, JM Schvartzman, S Hou, C Famulare, ... Cancer discovery 8 (12), 1540-1547, 2018 | 163 | 2018 |
| Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency VWK Silva, G Askan, TD Daniel, M Lowery, DS Klimstra, GK Abou-Alfa, ... Chinese clinical oncology 5 (5), 62-62, 2016 | 163 | 2016 |
| Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma MA Lowery, DP Kelsen, M Capanu, SC Smith, JW Lee, ZK Stadler, ... European Journal of Cancer 89, 19-26, 2018 | 154 | 2018 |
| Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a … A Cercek, T Boerner, BR Tan, JF Chou, M Gönen, TM Boucher, ... JAMA oncology 6 (1), 60-67, 2020 | 151 | 2020 |
| A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma EM O'Reilly, A Perelshteyn, WR Jarnagin, M Schattner, H Gerdes, ... Annals of surgery 260 (1), 142-148, 2014 | 149 | 2014 |
